Related Story

    Akero’s Efruxifermin Significantly Reverses Cirrhosis Due to MASH in 96-Week Phase 2b Study

    Akero’s Efruxifermin Significantly Reverses Cirrhosis Due to MASH in 96-Week Phase 2b Study

    21 postsHealthPharmaScience

    Akero Therapeutics announced preliminary topline results from its Phase 2b SYMMETRY study demonstrating that its FGF21 analog, efruxifermin, reversed liver scarring in patients with compensated cirrhosis (F4) due to MASH. At week 96, 39% of patients receiving efruxifermin achieved at least a one-stage improvement in fibrosis without worsening MASH, compared to 15% for placebo, reflecting a 24-point difference. In the intent-to-treat (ITT) analysis, 29% of the efruxifermin group showed improvement versus 12% for placebo. The significant results were observed in both completer and ITT analyses. Patients with cirrhosis due to MASH have limited treatment options outside of liver transplantation, with a median survival of about five years.

    Proposed Market

    First Regulatory Approval for Efruxifermin in MASH Cirrhosis by End of 2025?

    First Regulatory Approval for Efruxifermin in MASH Cirrhosis by End of 2025?

    2
    Akero Therapeutics

    Description

    Regulatory announcements from FDA, EMA, and other international bodies

    Market Options

    Related Polymarket Markets

    No similar markets found

    This could indicate a unique market opportunity that hasn't been explored yet.